Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine

Inventors

Khan, Shamsuddin Sultan • Catanzaro, John A. • Yuryev, Anton

Assignees

Neo7bioscience Inc

Abstract

As disclosed herein a precision based immunomolecular augmentation (PBIMA) high specificity patient profiling networked computer system, rapid therapeutic vaccine design method, and personalized vaccine, which utilizes immuno-molecular biopathway HLA affinity mapping and selection prediction ranking tools. This PBIMA approach comprises: Strategic-Selection, Molecular-Mapping, Antigen-Alignment, Receptor-Recognition, and Tactical Technology (SMART). The platform obtains data from a patient's genes and proteins as input. NGS data, including WES, WGS, ctDNA and cfDNA, RNAseq uses as input. PBIMA comprises a gene-protein-cell Cloud-based sequence editing interface to select the high confidence peptides. The PBIMA vaccine is a solution-based multi-purpose vaccine design strategy. PBIMA technology can produce therapeutic vaccines for cancer, autoimmune, neurodegenerative, inflammation-driven disease, and novel pathogen infection treatment. PBIMA therapeutic design is multi-mechanistic and broad-spectrum.

Core Innovation

The invention is a precision-based immunomolecular augmentation (PBIMA) computerized method for designing and treating a patient with customized therapeutic peptides or a peptide vaccine. The method receives patient transcriptomics data and patient urine proteomics data, and computes a precision data output of a vaccine composition specific to a patient's profile. The computed vaccine composition is configured to elicit an effective therapeutic response against a patient disease.

The computing includes identifying a plurality of therapeutic peptide sequences and ranking the plurality of therapeutic peptide sequences as a function of biomarker expression levels of an organoid to use in the vaccine composition. The method further includes conducting an immunopeptide synthesis and manufacturing of the vaccine composition. The patient is diagnosed with and/or is genetically predisposed to one or more diseases comprising cancer, autoimmune disease, neurodegenerative disease, and/or pathogenic infectious disease.

The related PBIMA apparatus includes at least a processor and a memory containing instructions for receiving patient transcriptomics data and patient urine proteomics data, computing a precision data output of a patient-specific vaccine composition, identifying and ranking therapeutic peptide sequences based on organoid biomarker expression levels, and conducting immunopeptide synthesis and manufacturing.

Claims Coverage

The document provides two independent claims: an independent PBIMA computerized method and an independent PBIMA apparatus. Across these independent claims, four core inventive features are covered: patient transcriptomics and urine proteomics inputs, computation of a patient-specific vaccine composition, identification and ranking of therapeutic peptide sequences using organoid biomarker expression levels, and immunopeptide synthesis and manufacturing.

Both independent claims define PBIMA as a computerized method or apparatus that uses patient transcriptomics and patient urine proteomics inputs to compute a vaccine composition, ranks therapeutic peptide sequences based on organoid biomarker expression levels, and includes immunopeptide synthesis and manufacturing for patients diagnosed with and/or genetically predisposed to cancer, autoimmune disease, neurodegenerative disease, and/or pathogenic infectious disease.

Stated Advantages

Documented Applications